Moreover, SPARE-Tau identified the largest effect size difference when we compared Aβ+ CU participants (not used for training) to Aβ- CU participants and was the strongest predictor of clinical progression and cognitive decline in the Aβ+ CU participants (hold-out validation group). This evidence concerns the gene MAPT and Mental deterioration.